Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FMmeds vs OurView Health

FMmeds
Graded #260

Lower grade

vs+4.3999999999999915
OurView Health
Graded #167

Higher grade

The verdict

OurView Health takes it — 67.6/100 to 63.2/100.

OurView Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOurView Health +30
46
76
Dose & formulationFMmeds +8
72
64
Clinical oversightOurView Health +9
70
79
Labs & monitoringEven
53
53
FulfillmentFMmeds +27
97
70
Contract termsFMmeds +2
47
45
FMmeds · left barOurView Health · right bar

The numbers

MetricFMmedsOurView Health
WeighScore63.2/10067.6/100
GradeCC
Scorecard rank#260#167
Semaglutide$225/mo (all doses, compounded)$75/mo (starting dose, compounded)
Tirzepatide$265/mo (all doses, compounded)$135/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
FMmeds

Graded #260 · C

Strengths

  • All 50 states plus DC covered, stated in the Terms
  • Operating LLC and full Manhattan Beach, CA address disclosed
  • Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
  • Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
  • Flat pricing across all dose strengths — no dose-escalation surcharge

Where it loses points

  • Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
  • Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
  • Clinical network not separately named
  • LegitScript Certified, but the specific ID isn't shown
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
OurView Health

Graded #167 · C

Strengths

  • Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
  • Clear product pricing with no contracts; medication shipped to your door (30-day supply)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
  • Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)

Where it loses points

  • 'Starting at' prices likely require Savings Club membership and/or a longer plan
  • Compounding pharmacy partner not named ('licensed third-party pharmacy')
  • 'LegitScript Approved' is stated on the site but was not independently verified here
  • Operating medical entity not clearly named (site operated by a marketing agency)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard